https://www.facebook.com/110747168294807/

TVNS India

Home
India
Bangalore
TVNS India

tVNS® stimulates the branch of the vagus nerve in the auricle through the skin.

tVNS is a non-invasive vagus nerve stimulation therapy and it is the only approved medical device in the world for the treatment of symptoms of sympathovagal imbalance.

21/04/2026

Performance is not just physical. It is regulated through the nervous system.

The vagus nerve plays a central role in activating the parasympathetic nervous system, supporting the shift from stress to recovery after intense training.

Transcutaneous vagus nerve stimulation (tVNS®) targets the afferent branch of the vagus nerve at the ear, offering a non-invasive way to support this process.

Research continues to explore how this approach may support heart rate regulation and heart rate variability, both key indicators of resilience, readiness, and recovery capacity.

By supporting autonomic balance, this form of neuromodulation may also contribute to improved sleep quality and cognitive clarity, which are essential for sustained high performance.

The difference between fatigue and progression often lies in how effectively the body can return to balance.

tVNS® is developed and manufactured in Germany and is the only non-invasive vagus nerve stimulation device approved under EU MDR (EU 2017/745), with demonstrated safety and clinical evaluation.

Explore how tVNS® supports recovery, focus, and long-term performance at www.tvns.health

17/04/2026

A 17-year-old patient struggling with treatment-resistant depression. Despite years of psychotherapy and medication, her symptoms remained severe, significantly affecting her daily life and overall well-being.

With the introduction of tVNS® therapy, a gradual and noticeable improvement was observed over time. Positive changes in mood, energy levels, and daily functioning marked an important turning point in her treatment journey.

Through a non-invasive neuromodulation approach, supporting the balance of the nervous system may offer a promising alternative especially in treatment-resistant cases.

15/04/2026

Modern treatment approaches should not only be effective, but also sustainable and patient-friendly.

tVNS® integrates neuromodulation into daily life with its non-invasive, medication-free approach.

Supported by clinical evaluation, this method delivers targeted stimulation via the vagus nerve, offering a structured alternative in treatment pathways.

✔ Certified medical device
✔ Clinically evaluated
✔ Non-invasive application
✔ Medication-free approach

Learn more: www.tvns.health

13/04/2026

Why do professional athletes choose tVNS®?

Performance isn't only built during training. It's shaped during recovery. By supporting the parasympathetic nervous system, tVNS® is used to help the body return to balance after intense physical stress. Athletes focus not only on strength and endurance, but also on recovery quality, sleep, and mental clarity. Because staying at the top level requires more than effort — it requires control.

Learn more at www.tvns.health

11/04/2026

Parkinson's is more than a diagnosis.

It is a daily journey that affects movement, independence, and quality of life.

On April 11, World Parkinson's Day reminds us of the importance of awareness, understanding, and support.

Because recognizing the condition is the first step — supporting people living with Parkinson's is what truly makes a difference.

09/04/2026

Why does non-invasive vagus nerve stimulation matter?

Because treatment approaches are evolving — toward solutions that are not only effective, but also more accessible and comfortable for patients.

tVNS® has been clinically evaluated and is approved in Europe under the EU Medical Device Regulation (MDR 2017/745) as a Class IIa medical device.

It represents a non-invasive approach to neuromodulation, designed to be integrated into structured clinical care.

07/04/2026

Today is World Health Day.

Health is not only about treatment; it is also about understanding, awareness, and long-term care.

This year's message: Together for health. Stand with science.

Scientific progress helps us better understand the body and develop more structured approaches to care. But progress only matters when it reaches people—when knowledge is shared and care becomes accessible.

Because building better health is not an individual effort. It happens together, through science.

06/04/2026

Performance is not just about pushing harder.
It's about how your body responds, adapts, and recovers.

tVNS® supports the body's natural regulatory systems through non-invasive vagus nerve stimulation, helping to improve focus, manage stress, and support recovery.

Used within a structured clinical context, neuromodulation is now being explored not only in healthcare, but also in performance optimization.

Because sustainable performance starts with balance.

04/04/2026

tVNS® is gaining attention across global media.

From major news outlets to scientific and clinical discussions, non-invasive vagus nerve stimulation continues to be explored in different contexts.

This growing visibility reflects increasing interest in structured neuromodulation — evaluated in academic and clinical environments.

For patients and clinicians, it means one thing:
a field that is being examined, discussed, and developed with scientific rigor.

tVNS® E is approved in Europe under EU Medical Device Regulation (MDR 2017/745).

Learn more at www.tvns.health

03/04/2026

Behind every statistic in Prader–Willi syndrome, there is a family trying to create calmer days.

Prader–Willi syndrome is a complex neurodevelopmental condition associated with hypothalamic dysfunction, altered autonomic regulation, and significant behavioural challenges. Emotional outbursts can be one of the most distressing aspects for patients and caregivers.

In clinical observation over a 12-month treatment period, 80% of patients using tVNS® recorded a reduction in the mean number of daily outbursts, with an average decrease of 50% compared to baseline.

tVNS® delivers transcutaneous stimulation to the afferent branch of the vagus nerve at the cymba conchae. Through this pathway, signals reach central autonomic and limbic networks that are involved in emotional regulation and behavioural control.

Approved in Europe under EU Medical Device Regulation (MDR 2017/745), tVNS® E is indicated for Prader–Willi syndrome, epilepsy, chronic migraine, and depression. Its external, non-invasive application allows integration into multidisciplinary care under medical supervision.

For clinicians, researchers, and families seeking deeper insight into study design, outcome measures, and mechanistic rationale, our team provides structured scientific information on request.

Responsible neuromodulation begins with evidence.

02/04/2026

Awareness starts with understanding.

People on the autism spectrum may experience the world differently but what they need is the same: to be understood, accepted, and supported.

Today is a reminder to take a small step towards a more inclusive world.

01/04/2026

Chronic migraine is more than a headache.

It is cancelled plans. Missed work. Days spent in dark rooms waiting for relief.

tVNS® was clinically evaluated in chronic migraine, where treatment was associated with a reduction of up to 50% in the number of migraine days after a 12-week period.

No implantation.

No systemic pharmacological exposure.

Defined clinical framework.

tVNS® E is approved in Europe under EU Medical Device Regulation (MDR 2017/745) and integrated into structured neurological care.

If you would like to find out more, please go to www.tvns.health and reach out to our expert team today!

Address

Bangalore

Website

facebook.com

Alerts

Be the first to know and let us send you an email when TVNS India posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to TVNS India:

Shortcuts

Want your business to be the top-listed Health & Beauty Business in Bangalore?